参考文献/References:
[1]曹毛毛,陈万青.GLOBOCAN 2020全球癌症统计数据解读[J].中国医学前沿杂志(电子版),2021,13(3):63-69.[2]邢力刚,马晓林.2021版《中华医学会肿瘤学分会肺癌临床诊疗指南》非小细胞肺癌诊疗更新专家解读[J].疑难病杂志,2022,21(6):557-560.[3]尹蕾,杨旭东,杨悦,等.中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J].实用肿瘤学杂志,2021,35(2):117-124.[4]马云飞,于明薇,李光达,等.肺癌血小板和中性粒细胞计数与淋巴细胞计数比值的临床特点及预后价值研究[J].中华肿瘤防治杂志,2021,28(12):921-926.[5]谭钦全,江冠铭,刘克军,等.血小板/淋巴细胞比值对表皮生长因子受体突变型晚期非小细胞肺癌靶向治疗效果及预后影响的观察性研究[J].癌症进展,2020,18(7):690-693.[6]孙珊珊,冯虎,毕莎杉.非小细胞肺癌预后标志物和预测相关性microRNA的研究[J].中国实验诊断学,2022,26(5):728-734.[7]赵坤宇,亓妍文,秦国慧,等.中性粒细胞淋巴细胞比值和淋巴细胞单核细胞比值对PD-1抑制剂治疗的晚期非小细胞肺癌患者预后的预测价值[J].郑州大学学报(医学版),2022,57(3):379-382.[8]Garshick MS,Tawil M,Barrett TJ,et al.Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis Via COX-1 (Cyclooxygenase-2)[J].Arteriosclerosis Thrombosis and Vascular Biology,2020,40(5):1340-1351.[9]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[10]Best MG,Sol N,Kooi I,et al.RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer,Multiclass,and Molecular Pathway Cancer Diagnostics[J].Cancer Cell,2015,28(5):666-676.[11]McAllister SS,Weinberg RA.The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis[J].Nat Cell Biol,2014,16(8):717-727.[12]Best MG,Wesseling P,Wurdinger T.Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring[J].Cancer Res,2018,78(13):3407-3412.[13]Liu L,Lin F,Ma X,et al.Tumor-educated platelet as liquid biopsy in lung cancer patients[J].Crit Rev Oncol Hematol,2020,146:102863.[14]Junqueira-Neto S,Batista IA,Costa JL,et al.Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA[J].Acta Cytol,2019,63(6):479-488.[15]Kinoshita T,Goto T.Links between Inflammation and Post-operative Cancer Recurrence[J].J Clin Med,2022,10(2):228.[16]韦琼,姚坚,吕学东.进展期非小细胞肺癌血清miR125b、巨噬细胞抑制因子1表达变化与抗PD-1/PD-L1单抗治疗疗效的关系[J].广东药科大学学报,2022,38(2):119-125.[17]朱飞,魏宇峰,王增,等.吉西他滨相关血小板减少对晚期非小细胞肺癌患者生存时间的影响[J].中国药师,2018,21(3):429-431.[18]樊华,弥鹏,杨波,等.肺癌患者外周血血小板参数检测分析及临床意义[J].现代检验医学杂志,2019,34(6):97-100.[19]韩蕃颉,王海滨,苏新云,等.3项血清肿瘤标志物、SAA及DCLK1联合检测在非小细胞癌患者预后判断中的价值[J].国际检验医学杂志,2021,42(17):2154-2157.[20]沈凯凯,吕镗烽.非小细胞肺癌患者血小板增多与临床病理的关系分析[J].临床肿瘤学杂志,2019,24(4):324-328.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(18):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(18):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(18):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]陈学敏,彭 琼.中性粒细胞与淋巴细胞比值联合癌胚抗原对结直肠癌早期诊断的研究[J].医学信息,2019,32(02):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
CHEN Xue-min,PENG Qiong.Early Diagnosis of Colorectal Cancer by Neutrophil-lymphocyte Ratio Combined with Carcinoembryonic Antigen[J].Journal of Medical Information,2019,32(18):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
[9]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(18):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(18):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[11]张冠卿,龙 勇,余海彬,等.治疗前NLR对ICIs治疗非小细胞肺癌患者的预后预测价值的Meta分析[J].医学信息,2024,37(07):30.[doi:10.3969/j.issn.1006-1959.2024.07.005]
ZHANG Guan-qing,LONG Yong,YU Hai-bin,et al.Meta-analysis of the Prognostic Value of Pre-treatment NLR in Patients with Non-small Cell Lung Cancer Treated with ICIs[J].Journal of Medical Information,2024,37(18):30.[doi:10.3969/j.issn.1006-1959.2024.07.005]